Best of ASCO - 2014 Annual Meeting

 

Welcome

Allogenic Stem Cell Transplantation

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase II study of myeloablative allogeneic hematopoietic stem cell transplantation (aHSCT) for acute lymphoblastic leukemia (ALL) in older patients using fludarabine and total body irradiation (Flu/TBI).

Omer Hassan Jamy

TPS7069

Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy.

Akash Mukherjee

7047

CMV reactivation in allogeneic hematopoietic stem cell transplant patients receiving post-transplant cyclophosphamide.

Paul Markowski

e18533

Development and validation of a novel disease risk model for patients with AML receiving allogeneic hematopoietic cell transplantation.

Piyanuch Kongtim

7016

HCT related toxicities and mortality in frail recipients.

Merve Pamukcuoglu

e18534

Healthcare implications of Clodtridium difficile infection after bone marrow transplant: Nationwide Readmission Database review.

Mohamed Hegazi

e18538

Impact of geriatric vulnerability on outcomes of older patients in allogeneic hematopoietic cell transplantation.

Richard Jirui Lin

7017

Inferior survival after microbiota injury: A multicenter allo-HCT study.

Jonathan U. Peled

7015

Intensive minimal residual disease monitoring to drive early intervention after allogeneic hematopoietic stem cell transplant for pediatric acute leukemia.

Thomas Pincez

e18531

Late infectious complications in hematopoietic cell transplantation survivors.

Eric Jessen Chow

7046

Mast cells as mediators of fibrosis and effector cell recruitment in dermal chronic graft-versus-host disease.

Ethan Strattan

7050

Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients.

Hind Rafei

7008

Outcomes of autologous blood collection prior to bone marrow harvest for matched unrelated donors.

Brian Hemendra Ramnaraign

e18535

Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study.

Uday R. Popat

7007

Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.

Ben Kent Tomlinson

7048

Role of killer cell immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML).

Hind Rafei

7049

The Transplant Optimization Program (TOP): Implementing a geriatric assessment (GA)-guided interdisciplinary clinic (IDC) prior to allogeneic hematopoietic cell transplantation (HCT) in older adults.

Benjamin Avi Derman

7045